問卷

TPIDB > Search Result

Search Result

篩選

List

15Cases

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).
  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2023-05-10 - 2025-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-12-15 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2020-11-18 - 2024-12-31

Phase II

Completed
An Exploratory, Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase IIa Study to Assess the Analgesic Activity of PAX-1 in Patients with Persistent Cancer Pain.
  • Condition/Disease

    Persistent Cancer Pain

  • Test Drug

    PAX-1

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2022-09-01 - 2025-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting7Sites

Terminated1Sites

2024-12-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-10-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2019-08-01 - 2025-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2024-01-22 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2024-11-15 - 2027-02-16

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2